Allogeneic small bowel transplantation with cyclosporine and donor whole-body irradiation

F. W. Frantz, D. J. Terris, C. W. Wyble, E. C. Halperin, F. Sanfilippo, M. W. Scroggs, G. Honore, R. R. Bollinger

Research output: Contribution to journalArticle

Abstract

This study was designed to investigate the ability of CsA to prevent rejection and GVHD in a totally allogeneic transplant between two rat strains with strong histoincompatibility as well as to determine the utility of combining donor WBI as an adjunct to CsA treatment of the recipient. The results obtained in our study indicate that CsA is insufficient as single therapy for preventing allograft rejection in totally allogeneic small bowel transplantation. Donor WBI as an adjunct to CsA immunosuppression may be effective in preventing rejection in totally allogeneic small bowel transplantation by reducing the immunogenicity of the graft. The effectiveness of irradiation in reducing graft immunogenicity and preventing host sensitization is perhaps best explained by its ability to destroy or impair the MHC class II antigen-presenting cells carried within the grafted tissue and/or lymphocytes that effect enhanced class II MHC antigen expression on vascular endothelium through production of γ-interferon and interleukin 2. Provided that irradiation does not cause irreversible impairment of bowel function, adjunctive immunosuppressive therapy with donor WBI may provide a significant benefit in allowing lower initial doses of CsA followed by more rapid tapering. Reduced nonspecific immunosuppression of recipients may decrease the incidence of deleterious side effects, one of the most serious of which, as evidenced in this study, is fatal infection.

Original languageEnglish (US)
Pages (from-to)193-196
Number of pages4
JournalTransplantation Proceedings
Volume20
Issue number1 SUPPL. 1
StatePublished - 1988
Externally publishedYes

Fingerprint

Whole-Body Irradiation
Cyclosporine
Transplantation
Histocompatibility Antigens Class II
Transplants
Immunosuppression
Vascular Endothelium
Antigen-Presenting Cells
Immunosuppressive Agents
Interferons
Interleukin-2
Allografts
Therapeutics
Lymphocytes
Incidence
Infection

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Frantz, F. W., Terris, D. J., Wyble, C. W., Halperin, E. C., Sanfilippo, F., Scroggs, M. W., ... Bollinger, R. R. (1988). Allogeneic small bowel transplantation with cyclosporine and donor whole-body irradiation. Transplantation Proceedings, 20(1 SUPPL. 1), 193-196.

Allogeneic small bowel transplantation with cyclosporine and donor whole-body irradiation. / Frantz, F. W.; Terris, D. J.; Wyble, C. W.; Halperin, E. C.; Sanfilippo, F.; Scroggs, M. W.; Honore, G.; Bollinger, R. R.

In: Transplantation Proceedings, Vol. 20, No. 1 SUPPL. 1, 1988, p. 193-196.

Research output: Contribution to journalArticle

Frantz, FW, Terris, DJ, Wyble, CW, Halperin, EC, Sanfilippo, F, Scroggs, MW, Honore, G & Bollinger, RR 1988, 'Allogeneic small bowel transplantation with cyclosporine and donor whole-body irradiation', Transplantation Proceedings, vol. 20, no. 1 SUPPL. 1, pp. 193-196.
Frantz FW, Terris DJ, Wyble CW, Halperin EC, Sanfilippo F, Scroggs MW et al. Allogeneic small bowel transplantation with cyclosporine and donor whole-body irradiation. Transplantation Proceedings. 1988;20(1 SUPPL. 1):193-196.
Frantz, F. W. ; Terris, D. J. ; Wyble, C. W. ; Halperin, E. C. ; Sanfilippo, F. ; Scroggs, M. W. ; Honore, G. ; Bollinger, R. R. / Allogeneic small bowel transplantation with cyclosporine and donor whole-body irradiation. In: Transplantation Proceedings. 1988 ; Vol. 20, No. 1 SUPPL. 1. pp. 193-196.
@article{58e0456c875c4d23aedd5cbfb2a66e4b,
title = "Allogeneic small bowel transplantation with cyclosporine and donor whole-body irradiation",
abstract = "This study was designed to investigate the ability of CsA to prevent rejection and GVHD in a totally allogeneic transplant between two rat strains with strong histoincompatibility as well as to determine the utility of combining donor WBI as an adjunct to CsA treatment of the recipient. The results obtained in our study indicate that CsA is insufficient as single therapy for preventing allograft rejection in totally allogeneic small bowel transplantation. Donor WBI as an adjunct to CsA immunosuppression may be effective in preventing rejection in totally allogeneic small bowel transplantation by reducing the immunogenicity of the graft. The effectiveness of irradiation in reducing graft immunogenicity and preventing host sensitization is perhaps best explained by its ability to destroy or impair the MHC class II antigen-presenting cells carried within the grafted tissue and/or lymphocytes that effect enhanced class II MHC antigen expression on vascular endothelium through production of γ-interferon and interleukin 2. Provided that irradiation does not cause irreversible impairment of bowel function, adjunctive immunosuppressive therapy with donor WBI may provide a significant benefit in allowing lower initial doses of CsA followed by more rapid tapering. Reduced nonspecific immunosuppression of recipients may decrease the incidence of deleterious side effects, one of the most serious of which, as evidenced in this study, is fatal infection.",
author = "Frantz, {F. W.} and Terris, {D. J.} and Wyble, {C. W.} and Halperin, {E. C.} and F. Sanfilippo and Scroggs, {M. W.} and G. Honore and Bollinger, {R. R.}",
year = "1988",
language = "English (US)",
volume = "20",
pages = "193--196",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "1 SUPPL. 1",

}

TY - JOUR

T1 - Allogeneic small bowel transplantation with cyclosporine and donor whole-body irradiation

AU - Frantz, F. W.

AU - Terris, D. J.

AU - Wyble, C. W.

AU - Halperin, E. C.

AU - Sanfilippo, F.

AU - Scroggs, M. W.

AU - Honore, G.

AU - Bollinger, R. R.

PY - 1988

Y1 - 1988

N2 - This study was designed to investigate the ability of CsA to prevent rejection and GVHD in a totally allogeneic transplant between two rat strains with strong histoincompatibility as well as to determine the utility of combining donor WBI as an adjunct to CsA treatment of the recipient. The results obtained in our study indicate that CsA is insufficient as single therapy for preventing allograft rejection in totally allogeneic small bowel transplantation. Donor WBI as an adjunct to CsA immunosuppression may be effective in preventing rejection in totally allogeneic small bowel transplantation by reducing the immunogenicity of the graft. The effectiveness of irradiation in reducing graft immunogenicity and preventing host sensitization is perhaps best explained by its ability to destroy or impair the MHC class II antigen-presenting cells carried within the grafted tissue and/or lymphocytes that effect enhanced class II MHC antigen expression on vascular endothelium through production of γ-interferon and interleukin 2. Provided that irradiation does not cause irreversible impairment of bowel function, adjunctive immunosuppressive therapy with donor WBI may provide a significant benefit in allowing lower initial doses of CsA followed by more rapid tapering. Reduced nonspecific immunosuppression of recipients may decrease the incidence of deleterious side effects, one of the most serious of which, as evidenced in this study, is fatal infection.

AB - This study was designed to investigate the ability of CsA to prevent rejection and GVHD in a totally allogeneic transplant between two rat strains with strong histoincompatibility as well as to determine the utility of combining donor WBI as an adjunct to CsA treatment of the recipient. The results obtained in our study indicate that CsA is insufficient as single therapy for preventing allograft rejection in totally allogeneic small bowel transplantation. Donor WBI as an adjunct to CsA immunosuppression may be effective in preventing rejection in totally allogeneic small bowel transplantation by reducing the immunogenicity of the graft. The effectiveness of irradiation in reducing graft immunogenicity and preventing host sensitization is perhaps best explained by its ability to destroy or impair the MHC class II antigen-presenting cells carried within the grafted tissue and/or lymphocytes that effect enhanced class II MHC antigen expression on vascular endothelium through production of γ-interferon and interleukin 2. Provided that irradiation does not cause irreversible impairment of bowel function, adjunctive immunosuppressive therapy with donor WBI may provide a significant benefit in allowing lower initial doses of CsA followed by more rapid tapering. Reduced nonspecific immunosuppression of recipients may decrease the incidence of deleterious side effects, one of the most serious of which, as evidenced in this study, is fatal infection.

UR - http://www.scopus.com/inward/record.url?scp=0023941945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023941945&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 193

EP - 196

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 1 SUPPL. 1

ER -